U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07295665) titled 'External Validation of Ischemia and Hemorrhage Risk Models in Patients With Coronary Heart Disease' on Dec. 03.
Brief Summary: Thrombosis formation is the core mechanism for the occurrence of major adverse cardiovascular and cerebrovascular events in patients with coronary heart disease. Antithrombotic therapy is one of the most important treatment methods for secondary prevention of coronary heart disease. Antithrombotic drugs, while reducing ischemic events, often significantly increase the risk of bleeding. How to balance the risk of recurrent ischemic events and bleeding events in patients with coronary heart disease is a major ...